West Haven Criteria Calculator- Free Hepatic Encephalopathy Grading Tool

West Haven Criteria Calculator – Free Hepatic Encephalopathy Grading Tool | Super-Calculator.com

About This West Haven Criteria Hepatic Encephalopathy Calculator

This West Haven Criteria calculator is designed for healthcare professionals, medical students, nursing staff, and clinical researchers who need to assess and grade the severity of hepatic encephalopathy at the bedside or in clinical studies. The tool systematically evaluates four key clinical domains (consciousness, orientation, behavior and intellectual function, and neuromuscular findings including asterixis) to determine the West Haven grade from Grade 0 (minimal hepatic encephalopathy) through Grade IV (coma), providing the standardized Conn score used in hepatology practice worldwide.

The calculator follows the grading framework established by Professor Harold Conn at Yale University and endorsed by the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) in their joint 2014 practice guidelines on hepatic encephalopathy management. It incorporates the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) classification of covert versus overt hepatic encephalopathy, where temporal disorientation marks the clinically significant transition from covert (Grades 0-I) to overt (Grades II-IV) encephalopathy.

The interactive severity spectrum visualization and risk ladder display provide immediate visual context for the assessed grade, while the individual domain score breakdown helps identify which clinical domains are most affected. Grade-specific clinical action recommendations cover care setting (outpatient, hospital ward, or ICU), monitoring needs (including Glasgow Coma Scale guidance for Grades III-IV), first-line and adjunctive pharmacological therapy (lactulose and rifaximin), precipitating factor identification, cerebral edema risk assessment in acute liver failure, and liver transplant evaluation criteria.

West Haven Criteria Calculator: Complete Guide to Hepatic Encephalopathy Grading and Clinical Assessment

Hepatic encephalopathy (HE) is a serious neuropsychiatric complication that arises when the liver fails to adequately filter toxins from the blood, leading to brain dysfunction. The West Haven Criteria, also known as the Conn score, is the most widely used clinical grading system for assessing the severity of hepatic encephalopathy. Developed by Professor Harold Conn and colleagues at Yale University, this semi-quantitative scale classifies HE into five grades (0 through IV) based on changes in consciousness, intellectual function, behavior, and neuromuscular findings. Accurate grading is essential for determining appropriate levels of care, guiding treatment decisions, monitoring disease progression, and standardizing clinical research across institutions worldwide.

This comprehensive guide explains the West Haven Criteria grading system in detail, including the clinical features of each grade, the distinction between covert and overt hepatic encephalopathy, the role of precipitating factors, diagnostic approaches, treatment strategies, and the limitations of the grading system. Whether you are a healthcare professional assessing a patient at bedside, a medical student studying hepatology, or a caregiver seeking to understand the condition better, this resource provides evidence-based information to support clinical decision-making.

What Is Hepatic Encephalopathy?

Hepatic encephalopathy is a brain dysfunction caused by liver insufficiency and/or portal-systemic blood shunting. It manifests as a wide spectrum of neurological and psychiatric abnormalities ranging from subclinical cognitive impairment, detectable only through specialized psychometric or neurophysiological testing, to deep coma. The condition is most commonly seen in patients with liver cirrhosis but can also occur in acute liver failure and in individuals with portal-systemic shunts without intrinsic liver disease.

The pathophysiology of hepatic encephalopathy is complex and multifactorial. The accumulation of ammonia in the blood is considered the primary mechanism, as the damaged liver cannot adequately convert ammonia to urea through the urea cycle. Ammonia crosses the blood-brain barrier and is metabolized by astrocytes, leading to osmotic stress, oxidative stress, neuroinflammation, and altered neurotransmission. Other contributing factors include systemic inflammation, alterations in the gut microbiome, manganese deposition in the basal ganglia, and changes in amino acid metabolism affecting neurotransmitter synthesis.

Hepatic encephalopathy is classified by the World Congress of Gastroenterology into three types based on the underlying etiology. Type A occurs in the setting of acute liver failure. Type B occurs in patients with portal-systemic bypass without intrinsic liver disease. Type C, the most common form, occurs in patients with liver cirrhosis and portal hypertension, often with portal-systemic shunts. The West Haven Criteria are applicable to all three types, providing a standardized framework for severity assessment regardless of the underlying cause.

History and Development of the West Haven Criteria

The West Haven Criteria were formulated by Professor Harold Conn (1925-2011) and his colleagues at Yale University during their investigation of the therapeutic efficacy of lactulose for hepatic encephalopathy in the 1970s. The grading system was later refined and formally adopted at the 11th World Congress of Gastroenterology in Vienna, Austria in 1998. The criteria have since become the standard clinical tool recommended by the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) in their joint 2014 practice guidelines on hepatic encephalopathy management.

The original scale defined four grades of clinically overt hepatic encephalopathy (Grades I through IV). When it became apparent that patients without clinically obvious symptoms could still demonstrate brain dysfunction on psychometric testing, a fifth category was added: Grade 0, representing minimal hepatic encephalopathy (MHE). Over time, the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) introduced a simplified dichotomy between covert HE (comprising MHE and Grade I) and overt HE (Grades II through IV), acknowledging the challenges in reliably distinguishing between Grade 0 and Grade I at the bedside.

West Haven Criteria Grading System

Grade 0 (Minimal) – Grade I (Covert) – Grade II (Overt) – Grade III (Overt) – Grade IV (Overt/Coma)

The West Haven Criteria grade hepatic encephalopathy from 0 to IV based on clinical assessment of consciousness, intellectual function, behavior, and neuromuscular findings. Grades 0-I are classified as covert HE, while Grades II-IV are classified as overt HE. The grading is semi-quantitative, meaning it relies on clinical judgment rather than precise numerical measurements.

Understanding Each West Haven Grade in Detail

Grade 0 – Minimal Hepatic Encephalopathy (MHE)

Grade 0, also referred to as minimal hepatic encephalopathy, represents the mildest form of brain dysfunction associated with liver disease. Patients at this grade have no clinically detectable changes in personality, behavior, or consciousness. However, specialized psychometric or neurophysiological testing reveals subtle cognitive deficits, particularly in the domains of attention, visuospatial ability, psychomotor speed, and working memory. Minimal hepatic encephalopathy is highly prevalent among patients with liver cirrhosis, affecting an estimated 22% to 74% of this population depending on the diagnostic tests used and the study population examined.

Despite the absence of overt clinical signs, minimal hepatic encephalopathy has significant real-world consequences. Affected individuals may experience impaired driving ability, reduced work productivity, increased risk of falls, and diminished health-related quality of life. Studies have demonstrated that patients with MHE have a higher rate of traffic accidents and impaired fitness to drive compared to cirrhotic patients without MHE. The condition also predicts the development of future episodes of overt hepatic encephalopathy and is associated with increased mortality.

Grade I – Trivial Lack of Awareness

Grade I hepatic encephalopathy is characterized by subtle changes that are often first noticed by the patient’s family members or close contacts rather than by the patient themselves or their healthcare provider during a routine examination. Clinical features include a trivial lack of awareness, euphoria or anxiety, shortened attention span, impaired ability to perform simple arithmetic (addition or subtraction), and an altered sleep-wake pattern with a tendency to sleep during the day and remain awake at night (sleep-wake inversion).

Grade I is often grouped with minimal HE under the umbrella of covert hepatic encephalopathy because of the difficulty in reliably detecting these subtle changes at the bedside. Inter-rater reliability for Grade I assessment is poor due to the subjective nature of identifying psychomotor slowing, personality shifts, and attention deficits without objective testing tools. The AASLD-EASL guidelines recommend that when clinical features do not clearly meet Grade II criteria (specifically, absence of at least temporal disorientation), neuropsychological or neurophysiological testing should be used to diagnose covert HE rather than relying on West Haven grading alone.

Grade II – Lethargy and Disorientation

Grade II marks the transition into overt hepatic encephalopathy and represents the most commonly encountered grade in clinical practice. The hallmark finding is disorientation for time, which may be accompanied by disorientation for place. Patients exhibit lethargy or apathy, inappropriate behavior, and obvious personality changes that are readily apparent to healthcare providers, not just family members. Asterixis (flapping tremor of the hands when the wrists are dorsiflexed) is typically first detectable at this grade, though it is not always present. Other motor findings may include slurred speech, ataxia, and hypoactive deep tendon reflexes.

The detection of temporal disorientation and asterixis at Grade II and above demonstrates good inter-rater reliability, making clinical assessment more consistent from this point forward. Patients with Grade II HE frequently require hospitalization, though not universally. Treatment focuses on identifying and correcting precipitating factors, initiating lactulose therapy to achieve two to three soft bowel movements per day, and considering rifaximin as adjunctive therapy, particularly for recurrent episodes.

Grade III – Somnolence to Semistupor

Grade III hepatic encephalopathy is characterized by marked somnolence progressing to semistupor. Patients are arousable and responsive to verbal stimuli but exhibit gross disorientation to time, place, and situation. Behavior may become bizarre or aggressive. Confusion is profound, and patients cannot perform even basic mental tasks. Hyperactive deep tendon reflexes, clonus, muscular rigidity, and a positive Babinski sign may be present on neurological examination. Asterixis may still be elicitable but often becomes less distinct as the level of consciousness deteriorates.

Patients at Grade III require hospital admission, frequently to an intensive care unit, due to the risk of aspiration, airway compromise, and rapid progression to coma. The Glasgow Coma Scale (GCS) should be used alongside the West Haven Criteria for patients at this grade to provide a more objective and granular assessment of the level of consciousness. Brain imaging (CT or MRI) should be considered to exclude alternative diagnoses such as intracranial hemorrhage, stroke, or brain lesions, particularly if this is the patient’s first episode or if the clinical presentation is atypical.

Grade IV – Coma

Grade IV represents the most severe manifestation of hepatic encephalopathy, in which the patient is in coma. The coma may be responsive or unresponsive to painful (noxious) stimuli. There is a complete loss of higher cortical function. Decerebrate or decorticate posturing may be observed. Deep tendon reflexes are absent, and the pupillary response may be sluggish or absent. In the context of acute liver failure, Grade IV HE carries a very high mortality rate and is a strong indicator for liver transplant evaluation.

Cerebral edema is a critical concern in patients with Grade IV HE, particularly those with acute liver failure. It is observed in approximately 75% of patients with acute liver failure who reach Grade IV encephalopathy, compared to only 25-35% at Grade III. Increased intracranial pressure (ICP) may manifest as systemic hypertension, bradycardia, and respiratory depression (Cushing triad). Management in the intensive care setting includes airway protection, ICP monitoring where available, osmotic therapy with mannitol or hypertonic saline, and urgent evaluation for liver transplantation.

Covert vs. Overt Hepatic Encephalopathy Classification (ISHEN)

Covert HE = Minimal HE (Grade 0) + Grade I | Overt HE = Grade II + Grade III + Grade IV

The International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) introduced this simplified two-category system to address the poor inter-rater reliability of distinguishing between Grades 0 and I. Covert HE requires specialized psychometric testing for diagnosis, while overt HE (Grade II and above) is detectable through standard clinical examination, with temporal disorientation being the key distinguishing feature.

Clinical Assessment Using the West Haven Criteria

Effective grading using the West Haven Criteria requires systematic clinical assessment across multiple domains. The examiner should evaluate the patient’s level of consciousness (alert, lethargic, somnolent, stuporous, or comatose), orientation (to time, place, person, and situation), intellectual function (ability to perform simple arithmetic, serial sevens, or recall tasks), behavior (appropriateness, personality changes, disinhibition), and neuromuscular function (presence of asterixis, tremor, hyperreflexia, rigidity, or clonus).

Asterixis is assessed by asking the patient to extend both arms, dorsiflex the wrists, and spread the fingers for 30 seconds. A positive finding consists of bilateral, asynchronous, non-rhythmic flapping movements of the hands. Asterixis is not specific to hepatic encephalopathy and can occur in other metabolic encephalopathies, including uremia, hypercarbia, and hypomagnesemia. It is also important to distinguish asterixis from the fine rhythmic tremor seen in alcohol withdrawal. The asterixis grading system (0 to 4) can be used alongside the West Haven Criteria to provide additional clinical information, as recommended by the U.S. Food and Drug Administration (FDA) for clinical trials.

A thorough clinical assessment should also document the time course (episodic, recurrent if more than two episodes within six months, or persistent), identify precipitating factors, and classify the type of hepatic encephalopathy (A, B, or C). Common precipitating factors include infection (the most common, accounting for approximately 31% of episodes), constipation (29%), dehydration and electrolyte imbalances (particularly hyponatremia and hypokalemia), gastrointestinal bleeding, excessive dietary protein intake, use of sedative medications (benzodiazepines, opioids), non-adherence to lactulose therapy, and TIPS (transjugular intrahepatic portosystemic shunt) placement.

Key Point: Temporal Disorientation as the Gateway to Overt HE

The presence of at least temporal disorientation is the key clinical feature that distinguishes overt hepatic encephalopathy (Grade II and above) from covert HE. When temporal disorientation is present, the West Haven Criteria can be applied with good inter-rater reliability. When it is absent but HE is suspected, specialized psychometric testing (such as the Psychometric Hepatic Encephalopathy Score or the Stroop test) should be used for diagnosis.

Precipitating Factors and Their Role in Hepatic Encephalopathy

Precipitating factors can be identified in nearly all episodes of episodic hepatic encephalopathy type C. Their identification and correction is a cornerstone of management and often leads to rapid clinical improvement. The most common precipitating factors identified in clinical trials and observational studies include infections (particularly spontaneous bacterial peritonitis, urinary tract infections, and pneumonia), constipation, gastrointestinal bleeding, dehydration from excessive diuretic use or poor oral intake, electrolyte disturbances (hyponatremia, hypokalemia, metabolic alkalosis), use of psychoactive medications, dietary protein excess, renal failure, and portal vein thrombosis.

Multiple precipitating factors may coexist in the same patient, and failure to identify and correct all contributing factors can lead to treatment failure and prolonged encephalopathy. A systematic approach to precipitant identification should include blood cultures and infection screening, complete metabolic panel with electrolytes and renal function, complete blood count, urinalysis, chest radiograph, abdominal paracentesis if ascites is present, medication reconciliation, and assessment of lactulose compliance and stool frequency.

Key Point: Always Search for Precipitating Factors

Every episode of overt hepatic encephalopathy should prompt a thorough search for precipitating factors. Infection is the single most common trigger, followed by constipation and dehydration. Treating the precipitating factor is often more important than treating the encephalopathy itself, as correction of the underlying trigger frequently leads to resolution of the HE episode.

Diagnostic Tools Beyond the West Haven Criteria

While the West Haven Criteria remain the primary clinical tool for grading overt hepatic encephalopathy, several complementary diagnostic methods exist for assessing covert HE and providing more objective measurements. The Psychometric Hepatic Encephalopathy Score (PHES) is a standardized battery of five paper-and-pencil tests (Number Connection Tests A and B, the Digit Symbol Test, the Serial Dotting Test, and the Line Tracing Test) that assesses psychomotor speed, attention, and visuospatial function. The PHES is the best-validated psychometric tool for diagnosing minimal hepatic encephalopathy.

The Animal Naming Test, in which the patient is asked to name as many animals as possible in 60 seconds, is the only validated bedside screening test for covert HE. A score below a regionally adjusted cutoff (typically fewer than 10-15 animals per minute depending on age and education level) suggests covert HE. The Stroop test (available as a smartphone application called EncephalApp) assesses psychomotor speed and cognitive flexibility and has been validated across multiple populations. Other tests include the Inhibitory Control Test, the Continuous Reaction Time Test, the Critical Flicker Frequency test, and electroencephalography (EEG), which may reveal characteristic triphasic waves in more advanced HE.

The Hepatic Encephalopathy Scoring Algorithm (HESA) was developed to provide a more objective assessment by combining clinical indicators with simple neuropsychological tests. Research has identified the most effective clinical indicators for each grade: lethargy and disorientation to time for Grade II, somnolence and disorientation to place for Grade III, and lack of verbal, eye, or motor response for Grade IV. Bispectral index (BIS) monitoring has shown promise as an objective tool, with specific cutoff values proposed for each grade (90.5 for minimal HE, 77.5 for Grade I, 70.5 for Grade II, 60.5 for Grade III, and 50.5 for Grade IV), though this remains primarily a research tool.

The Glasgow Coma Scale and Its Role in Higher-Grade HE

The AASLD-EASL guidelines recommend adding the Glasgow Coma Scale (GCS) assessment for patients with West Haven Grade III or IV hepatic encephalopathy. The GCS provides a more objective and granular assessment of consciousness level through standardized scoring of eye opening (1-4), verbal response (1-5), and motor response (1-6), yielding a total score from 3 to 15. This is particularly valuable in the intensive care setting for monitoring trends in neurological status, communicating between providers, and guiding decisions about airway management and intracranial pressure monitoring.

A GCS score of 8 or below generally indicates the need for intubation and mechanical ventilation to protect the airway. In the context of acute liver failure with hepatic encephalopathy, serial GCS assessments help track the rate of neurological deterioration, which has prognostic significance. Rapid decline from Grade II to Grade IV carries a worse prognosis than gradual progression and may indicate the need for more urgent transplant evaluation.

Treatment of Hepatic Encephalopathy by Grade

Treatment strategies for hepatic encephalopathy are guided by the severity grade, with general management principles applying across all grades and additional interventions required as severity increases. For all grades, the identification and treatment of precipitating factors is paramount. Nutritional support should ensure adequate caloric intake (35-40 kcal/kg/day) and protein intake (1.2-1.5 g/kg/day), as protein restriction is no longer recommended and may worsen sarcopenia, which itself is a risk factor for HE.

For covert HE (Grades 0-I), treatment is not routinely recommended by current guidelines unless the condition affects daily functioning, employment, driving ability, or public safety. When treatment is initiated, lactulose is the first-line agent. For overt HE (Grades II-IV), lactulose should be administered orally or via nasogastric tube, titrated to achieve two to three soft bowel movements per day. Rifaximin (a non-absorbable antibiotic) is recommended as add-on therapy to lactulose for the prevention of recurrent episodes of overt HE after the second episode, based on strong evidence from randomized controlled trials demonstrating reduced recurrence rates.

For Grade III HE, intensive care monitoring is essential due to the risk of aspiration and airway compromise. Lactulose enemas may be used if oral administration is not possible. For Grade IV HE (coma), airway protection through intubation, management of cerebral edema (particularly in acute liver failure), and urgent liver transplant evaluation are priorities. Intravenous L-ornithine-L-aspartate (LOLA) may be considered as adjunctive therapy to reduce ammonia levels, though evidence for its efficacy in severe HE is mixed.

Key Point: Lactulose as First-Line Treatment

Lactulose (a non-absorbable disaccharide) remains the first-line pharmacological treatment for hepatic encephalopathy across all grades. It works by acidifying the colonic environment, converting ammonia to non-absorbable ammonium, promoting osmotic catharsis, and altering the gut microbiome to reduce ammonia-producing bacteria. The target is two to three soft bowel movements per day. Over-treatment leading to diarrhea and dehydration can paradoxically worsen HE.

Limitations of the West Haven Criteria

Despite being the most widely used grading system for hepatic encephalopathy, the West Haven Criteria have several recognized limitations. The most significant is poor inter-rater reliability at Grade I, where subtle changes in personality, mood, and attention are difficult to detect consistently across different examiners. This led to the recommendation that Grade I should not be diagnosed based on clinical assessment alone but should be confirmed with psychometric or neurophysiological testing.

The grading system is semi-quantitative and relies heavily on clinical judgment, making it susceptible to examiner bias and experience level. There is no standardized scoring algorithm, and the criteria do not specify exactly which clinical features must be present to assign a particular grade. Motor symptoms such as asterixis are not strictly tied to specific grades and may be present or absent independently of the level of consciousness or cognitive impairment. The scale is ordinal, meaning the difference between grades is not necessarily equal in terms of clinical significance or prognosis.

Additionally, the West Haven Criteria do not account for the episodic and fluctuating nature of hepatic encephalopathy, as a patient’s grade can change rapidly over hours. The criteria also do not incorporate laboratory values (such as ammonia levels), imaging findings, or electrophysiological data, relying entirely on bedside clinical assessment. Despite these limitations, the West Haven Criteria remain the standard because of their simplicity, widespread familiarity, and practical utility at the bedside.

Prognosis and Clinical Significance of HE Grading

The severity of hepatic encephalopathy as assessed by the West Haven Criteria has important prognostic implications. Each episode of overt HE is associated with an increased risk of recurrence and increased one-year mortality. Higher-grade HE carries a worse prognosis than lower-grade HE. A study of hospitalized patients with hepatic encephalopathy reported a 44% survival probability at 12 months and 35% at 24 months, underscoring the seriousness of this complication.

Even after successful treatment of an overt HE episode, residual cognitive deficits may persist despite an apparent return to normal mental status. The severity of these persistent neurological impairments tends to be greater in patients who have experienced multiple episodes of overt HE. This phenomenon of cumulative neurological injury highlights the importance of secondary prophylaxis (with lactulose and rifaximin) to prevent recurrent episodes and the need for ongoing neuropsychological monitoring even in patients who appear clinically recovered.

The HE grade also informs decisions about liver transplant evaluation. In patients with acute liver failure, the development of Grade III or IV HE is a strong indicator for listing for emergency liver transplantation, as the risk of cerebral edema and death increases substantially at these grades. In patients with cirrhosis, recurrent or persistent HE despite optimal medical therapy is itself an indication for transplant evaluation, regardless of the MELD (Model for End-Stage Liver Disease) score.

HE Type Classification: Types A, B, and C

The classification of hepatic encephalopathy by type provides important etiological context that complements the West Haven severity grading. Type A HE occurs in the setting of acute liver failure, which may be caused by viral hepatitis, drug-induced liver injury (particularly acetaminophen overdose), autoimmune hepatitis, Wilson disease, or other causes of fulminant hepatic failure. Type A HE often progresses rapidly and carries a high risk of cerebral edema, making it a medical emergency requiring intensive care management and urgent transplant evaluation.

Type B HE occurs in patients with portal-systemic bypass (shunting) without underlying intrinsic liver disease. This is relatively uncommon and may be seen in patients with congenital portosystemic shunts or surgical shunts. Type C HE, the most common form, occurs in patients with liver cirrhosis and portal hypertension. It may be episodic (triggered by a precipitating factor), recurrent (more than two episodes within six months), or persistent (a baseline pattern of behavioral alterations with superimposed episodes of worsening). Type C HE is the most commonly encountered in clinical practice and the form most frequently graded using the West Haven Criteria.

Asterixis Grading as a Complementary Assessment

Asterixis, also known as flapping tremor or liver flap, is a commonly observed neuromotor sign in hepatic encephalopathy that results from the inability to maintain sustained posture due to intermittent loss of muscle tone. It is assessed by asking the patient to hold both arms extended with wrists dorsiflexed and fingers spread for 30 seconds. The resulting bilateral, asynchronous, non-rhythmic flapping movements can be graded on a separate 0-4 scale alongside the West Haven Criteria.

The asterixis grading system assigns Grade 0 for no flap detected, Grade 1 for rare flaps (occurring only a few times during the 30-second observation), Grade 2 for intermittent flaps (occurring irregularly), Grade 3 for frequent flaps (almost continuous), and Grade 4 when testing is not possible because the patient cannot maintain the required position. The U.S. FDA has recommended that asterixis grading be included as a component of HE assessment in clinical trials to provide additional sensitivity, particularly at the lower end of the West Haven scale where the Conn score alone has poor discriminant power.

Validation Across Diverse Populations

The West Haven Criteria were originally developed in Western populations, but they have been applied globally across diverse ethnic, geographic, and cultural contexts. The grading system has been used in clinical trials and observational studies conducted in North America, Europe, Asia, South America, Africa, and the Middle East. The clinical features assessed by the criteria (consciousness level, orientation, behavior, neuromuscular function) are universal neurological parameters that can be evaluated regardless of cultural background.

However, several factors may influence the interpretation and application of the criteria across different populations. Language and cultural barriers may affect the assessment of orientation, intellectual function, and personality changes. Educational level influences performance on cognitive tests, and normative values for psychometric tests used to diagnose covert HE vary by region. The prevalence of different etiologies of liver disease (hepatitis B-predominant in East Asia, hepatitis C in the Middle East, alcohol-related in Western countries, non-alcoholic fatty liver disease globally) may influence the clinical presentation and course of HE. Despite these considerations, the fundamental grading framework of the West Haven Criteria remains applicable across populations, and it is endorsed by international hepatology societies including the AASLD, EASL, and the Asia-Pacific Association for the Study of the Liver (APASL).

Regional Variations and Alternative Grading Systems

While the West Haven Criteria are the most widely used grading system globally, several alternative and complementary tools exist. The Glasgow Coma Scale (GCS) is recommended as a supplement for Grades III-IV to provide more objective assessment. The Clinical Hepatic Encephalopathy Staging Scale (CHESS) was developed as a simpler bedside tool with potentially better inter-rater reliability than the West Haven Criteria. The Hepatic Encephalopathy Scoring Algorithm (HESA) combines clinical indicators with neuropsychological tests for more objective grading.

For covert hepatic encephalopathy, the Psychometric Hepatic Encephalopathy Score (PHES) is the best-validated diagnostic battery, though it requires trained personnel and age/education-adjusted normative data. The Critical Flicker Frequency (CFF) test offers an objective, quantitative assessment that is relatively culture-independent. The EncephalApp Stroop test, available as a smartphone application, provides a portable, validated screening tool that has been tested across multiple international populations. Some centers use electroencephalography (EEG) to detect subclinical changes, though this is more commonly a research tool than a routine clinical assessment.

Ammonia Levels and Their Relationship to HE Grading

Blood ammonia levels are frequently measured in the evaluation of hepatic encephalopathy, but their relationship to West Haven grading is complex and imperfect. While elevated ammonia is central to the pathophysiology of HE, serum ammonia levels do not reliably correlate with the severity of encephalopathy as determined by West Haven grading. A patient may have markedly elevated ammonia levels with minimal symptoms, while another patient with only modestly elevated ammonia may present with Grade III or IV HE.

Current guidelines state that a normal ammonia level brings the diagnosis of hepatic encephalopathy into question, making it useful as a negative predictor. However, ammonia levels should not be used for diagnosis, staging, or monitoring of HE. Treatment decisions should be based on clinical assessment, not ammonia values. The poor correlation between ammonia levels and HE grade is thought to reflect the multifactorial nature of the condition, with systemic inflammation, oxidative stress, and other metabolic derangements contributing to brain dysfunction beyond ammonia toxicity alone.

Cerebral Edema Risk by HE Grade

In patients with acute liver failure, the risk of cerebral edema increases progressively with higher West Haven grades. Cerebral edema is relatively rare in patients with Grade I or II encephalopathy but is observed in approximately 25-35% of patients who reach Grade III and about 75% of those with Grade IV HE. Increased intracranial pressure (ICP) from cerebral edema can cause brain herniation, which is the leading cause of death in acute liver failure. Clinical signs of elevated ICP include systemic hypertension, bradycardia, and respiratory depression (the Cushing triad), seizures, and abnormal brainstem reflexes.

Cerebral edema is much less common in chronic liver disease with cirrhosis, where the brain may have adapted to chronic hyperammonemia through compensatory mechanisms. However, it can still occur in the setting of acute-on-chronic liver failure, where an acute precipitant causes rapid decompensation in a patient with preexisting cirrhosis. The distinction between the risk profiles of acute liver failure and chronic cirrhosis underscores the importance of classifying HE by type (A, B, or C) in addition to grading by the West Haven Criteria.

Secondary Prophylaxis and Long-Term Management

After the first episode of overt hepatic encephalopathy, secondary prophylaxis should be initiated to prevent recurrence. Lactulose is the first-line agent for secondary prophylaxis, titrated to maintain two to three soft bowel movements daily. After the second episode of overt HE, rifaximin should be added to lactulose, as the combination has been shown to significantly reduce the risk of recurrence compared to lactulose alone. Long-term adherence to therapy is essential, as non-compliance with lactulose is itself a common precipitating factor for recurrent episodes.

Other aspects of long-term management include addressing the underlying liver disease (antiviral therapy for hepatitis B or C, alcohol abstinence counseling, management of metabolic risk factors), optimizing nutritional status with adequate protein and caloric intake, screening for and treating sarcopenia (muscle wasting, which reduces the body’s capacity to metabolize ammonia through glutamine synthesis in skeletal muscle), managing portal hypertension, and regular follow-up with serial assessments for covert HE using validated psychometric tools.

Key Point: Ammonia Is Not Reliable for Grading or Monitoring

Blood ammonia levels do not correlate reliably with hepatic encephalopathy grade. A normal ammonia level makes the diagnosis of HE less likely, but elevated levels do not determine the grade of severity. Treatment decisions should be based on clinical assessment using the West Haven Criteria, not on ammonia values. Serial ammonia measurements should not be used to monitor treatment response.

Special Populations and Considerations

Certain patient populations require special consideration when applying the West Haven Criteria. In patients with acute liver failure (Type A HE), encephalopathy may progress very rapidly from Grade I to Grade IV within hours, and the risk of cerebral edema mandates early transfer to a transplant center, ideally before Grade III is reached. In post-TIPS patients, HE may develop de novo or worsen after shunt placement, occurring in approximately 25-45% of patients. If medical management fails, TIPS revision or occlusion may be necessary.

Elderly patients with cirrhosis may present with baseline cognitive impairment from other causes (dementia, cerebrovascular disease), making it challenging to attribute changes in mental status solely to hepatic encephalopathy. Pediatric patients require age-appropriate assessment of cognitive and motor function. Patients with alcohol use disorder require careful differentiation between hepatic encephalopathy and alcohol withdrawal, as both can present with altered mental status, tremor, and agitation, but the management differs significantly. A tremor is typically a fine, rhythmic movement, while asterixis is a coarse, non-rhythmic flapping of the hands.

Frequently Asked Questions

What are the West Haven Criteria for hepatic encephalopathy?

The West Haven Criteria, also known as the Conn score, are the most widely used clinical grading system for assessing the severity of hepatic encephalopathy (HE). Developed by Professor Harold Conn at Yale University, the system classifies HE into five grades (0 through IV) based on clinical assessment of consciousness, intellectual function, behavior, and neuromuscular findings. Grade 0 represents minimal HE detectable only by psychometric testing, Grade I involves subtle changes in awareness and attention, Grade II features lethargy and disorientation, Grade III involves somnolence to semistupor, and Grade IV is coma. The criteria are recommended by the AASLD and EASL for clinical assessment and research standardization.

How do you assess hepatic encephalopathy grade at the bedside?

Bedside assessment of HE grade involves evaluating several clinical domains. First, assess the level of consciousness (alert, lethargic, somnolent, stuporous, or comatose). Next, test orientation by asking the patient about the current date, day of the week, location, and situation. Evaluate intellectual function through simple arithmetic tasks. Observe behavior for personality changes, inappropriate actions, or disinhibition. Finally, check for asterixis by asking the patient to extend their arms with wrists dorsiflexed for 30 seconds. The presence of temporal disorientation generally indicates at least Grade II (overt HE). For Grades III-IV, add the Glasgow Coma Scale for more objective assessment.

What is the difference between covert and overt hepatic encephalopathy?

Covert hepatic encephalopathy includes minimal HE (Grade 0) and Grade I, where cognitive deficits are subtle and not readily apparent on routine clinical examination. Diagnosis requires specialized psychometric or neurophysiological testing. Overt hepatic encephalopathy encompasses Grades II through IV, where clinical signs are apparent to the examiner without specialized testing. The key distinguishing feature is the presence of at least temporal disorientation, which marks the transition from covert to overt HE. This classification was introduced by ISHEN to address the poor inter-rater reliability of distinguishing between Grades 0 and I.

What is asterixis and how is it tested?

Asterixis, also called flapping tremor or liver flap, is a characteristic neuromotor sign of hepatic encephalopathy caused by intermittent loss of muscle tone. It is tested by asking the patient to hold both arms extended with wrists dorsiflexed and fingers spread open for 30 seconds. The examiner observes for bilateral, asynchronous, non-rhythmic flapping movements of the hands. Asterixis is typically first detectable at West Haven Grade II and may become less distinct as consciousness deteriorates in Grades III-IV. It is important to note that asterixis is not specific to HE and can occur in other metabolic encephalopathies such as uremia and hypercarbia.

What are the most common precipitating factors for hepatic encephalopathy?

Infections are the most common precipitating factor, accounting for approximately 31% of HE episodes. These include spontaneous bacterial peritonitis, urinary tract infections, and pneumonia. Constipation is the second most common trigger (approximately 29%), followed by dehydration and electrolyte imbalances (hyponatremia, hypokalemia), gastrointestinal bleeding, use of sedative medications (benzodiazepines, opioids), non-adherence to lactulose therapy, excessive dietary protein intake, and post-TIPS placement. Multiple precipitants may coexist, and systematic evaluation for all potential triggers is essential for effective management.

Can ammonia levels be used to grade hepatic encephalopathy severity?

No, blood ammonia levels should not be used to grade, diagnose, or monitor hepatic encephalopathy. While elevated ammonia is central to the pathophysiology of HE, serum levels do not reliably correlate with the clinical grade. A patient may have very high ammonia with minimal symptoms or moderate ammonia with severe encephalopathy. Current AASLD-EASL guidelines state that a normal ammonia level makes HE less likely but that elevated levels do not determine severity. Treatment decisions should be based on clinical assessment using the West Haven Criteria, not on ammonia values.

What is the treatment for hepatic encephalopathy?

Treatment depends on the grade of HE. For all grades, identifying and correcting precipitating factors is the most important step. Lactulose is the first-line pharmacological treatment, titrated to achieve two to three soft bowel movements per day. Rifaximin is added as adjunctive therapy after the second episode of overt HE. Nutritional support should provide adequate calories (35-40 kcal/kg/day) and protein (1.2-1.5 g/kg/day) without protein restriction. Grade III patients need ICU monitoring for airway protection, and Grade IV patients may require intubation, management of cerebral edema, and urgent liver transplant evaluation.

How does hepatic encephalopathy affect prognosis?

Hepatic encephalopathy is a serious prognostic indicator. Each episode of overt HE increases the risk of recurrence and is associated with increased one-year mortality. A study of hospitalized HE patients reported only 44% survival at 12 months and 35% at 24 months. Higher-grade HE carries a worse prognosis than lower-grade HE. Even after treatment, residual cognitive deficits may persist. In acute liver failure, Grade III-IV HE is a strong indicator for emergency liver transplant listing due to the high risk of cerebral edema and death. In cirrhosis, recurrent or persistent HE is itself an indication for transplant evaluation.

What is minimal hepatic encephalopathy and why does it matter?

Minimal hepatic encephalopathy (MHE) is the mildest form of HE, corresponding to West Haven Grade 0. Patients have no clinically detectable neurological abnormalities, but specialized psychometric testing reveals subtle deficits in attention, visuospatial ability, psychomotor speed, and working memory. MHE affects 22-74% of cirrhotic patients and has significant real-world consequences including impaired driving ability, increased traffic accidents, reduced work productivity, increased fall risk, and diminished quality of life. MHE also predicts future episodes of overt HE and is associated with increased mortality.

When should the Glasgow Coma Scale be used alongside the West Haven Criteria?

The Glasgow Coma Scale (GCS) should be added to the West Haven Criteria assessment for patients with Grade III or IV hepatic encephalopathy, as recommended by the AASLD-EASL guidelines. The GCS provides a more objective and granular assessment of consciousness through standardized scoring of eye opening (1-4), verbal response (1-5), and motor response (1-6). It is particularly valuable in the intensive care setting for monitoring trends, communicating between providers, and guiding decisions about airway management. A GCS score of 8 or below generally indicates the need for intubation.

What is the difference between HE Types A, B, and C?

Type A hepatic encephalopathy occurs in the setting of acute liver failure from causes such as viral hepatitis, drug toxicity, or autoimmune hepatitis. It often progresses rapidly with high risk of cerebral edema. Type B occurs in patients with portal-systemic bypass (shunting) without intrinsic liver disease, which is relatively uncommon. Type C, the most common form, occurs in patients with liver cirrhosis and portal hypertension. The West Haven Criteria are used to grade severity in all three types. The type classification is important because management priorities differ: Type A often requires transplant evaluation, while Type C focuses on precipitant correction and medical therapy.

What is the role of rifaximin in hepatic encephalopathy treatment?

Rifaximin is a non-absorbable antibiotic that acts locally in the gut to reduce ammonia-producing bacteria and modulate the intestinal microbiome. It is recommended as add-on therapy to lactulose for secondary prophylaxis of hepatic encephalopathy, particularly after the second episode of overt HE. A landmark randomized controlled trial demonstrated that rifaximin plus lactulose significantly reduced the risk of HE recurrence compared to lactulose alone. Rifaximin has excellent safety profile with minimal systemic absorption, and it is generally well-tolerated for long-term use. It is not recommended as monotherapy but as an adjunct to lactulose.

Can hepatic encephalopathy be reversed?

Hepatic encephalopathy is potentially reversible with appropriate treatment, particularly when a precipitating factor is identified and corrected. Acute episodes of overt HE often improve with lactulose therapy and precipitant management. However, the degree of reversibility depends on the severity and duration of the episode, the underlying liver disease, and the number of previous episodes. Repeated episodes of overt HE can cause cumulative neurological injury, leading to persistent cognitive deficits even after apparent clinical recovery. Liver transplantation can reverse HE in most cases, though some patients may have residual neurological impairment post-transplant.

How reliable are the West Haven Criteria?

The reliability of the West Haven Criteria varies by grade. Grades II through IV demonstrate good inter-rater reliability because the clinical features (temporal disorientation, profound confusion, somnolence, coma) are relatively easy to identify consistently across different examiners. Grade I, however, has poor inter-rater reliability due to the subjective nature of detecting subtle changes like psychomotor slowing and mood shifts. This limitation led the ISHEN to recommend that Grades 0 and I be combined as covert HE, diagnosed by psychometric testing rather than clinical assessment alone. Despite these limitations, the criteria remain the standard due to their simplicity and widespread familiarity.

What is the risk of cerebral edema in hepatic encephalopathy?

The risk of cerebral edema in hepatic encephalopathy depends on both the type and grade. In acute liver failure (Type A), cerebral edema is relatively rare at Grades I-II but occurs in approximately 25-35% of patients at Grade III and about 75% at Grade IV. Cerebral edema can cause increased intracranial pressure, brain herniation, and death. In chronic liver disease with cirrhosis (Type C), cerebral edema is much less common due to compensatory mechanisms. The risk increases in the setting of acute-on-chronic liver failure. Management includes osmotic therapy, head-of-bed elevation, and urgent transplant evaluation.

Should protein intake be restricted in hepatic encephalopathy?

No, protein restriction is no longer recommended for patients with hepatic encephalopathy. Current guidelines recommend adequate protein intake of 1.2-1.5 g/kg/day along with total caloric intake of 35-40 kcal/kg/day. Protein restriction was historically practiced but has been shown to worsen sarcopenia (muscle wasting), which paradoxically increases the risk of HE because skeletal muscle is an important site for ammonia metabolism through glutamine synthesis. Branched-chain amino acid supplements may be considered for patients who are intolerant of dietary protein, but routine protein restriction should be avoided.

What psychometric tests are used to diagnose minimal hepatic encephalopathy?

The Psychometric Hepatic Encephalopathy Score (PHES) is the best-validated battery, consisting of five paper-and-pencil tests: Number Connection Tests A and B, the Digit Symbol Test, the Serial Dotting Test, and the Line Tracing Test. The Animal Naming Test (naming as many animals as possible in 60 seconds) is the only validated bedside screening test. The EncephalApp Stroop test is a validated smartphone-based tool. Other tests include the Inhibitory Control Test, Continuous Reaction Time Test, Critical Flicker Frequency test, and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Results are interpreted against age and education-adjusted norms.

How does hepatic encephalopathy affect driving ability?

Even minimal hepatic encephalopathy (Grade 0) significantly impairs driving ability. Studies have demonstrated that patients with MHE have slower reaction times, impaired attention, reduced visuospatial processing, and difficulty with divided attention, all of which are critical for safe driving. Research has shown increased rates of traffic violations and motor vehicle accidents in patients with MHE compared to those without. Some jurisdictions require fitness-to-drive assessment for patients with known liver cirrhosis. Screening for MHE is recommended before certifying driving fitness, and patients with any grade of overt HE should be advised against driving until the condition resolves.

What is the Animal Naming Test for hepatic encephalopathy?

The Animal Naming Test is the only validated bedside screening test for covert hepatic encephalopathy. The patient is asked to name as many animals as possible within 60 seconds. The test assesses verbal fluency, semantic memory, and executive function. A score below a regionally adjusted cutoff (typically fewer than 10-15 animals per minute, depending on age and education level) suggests covert HE. The test is quick, simple, requires no special equipment, and can be performed by any healthcare provider. It has been validated in multiple populations and is recommended by the AASLD-EASL guidelines as a screening tool when formal psychometric testing is not available.

What is the EncephalApp Stroop test?

The EncephalApp Stroop test is a validated smartphone-based application developed for screening covert hepatic encephalopathy. The test presents color words (red, blue, green) that are either congruent (the word matches the ink color) or incongruent (the word does not match the ink color). The patient must identify the ink color as quickly as possible. The test measures psychomotor speed, cognitive flexibility, and response inhibition. It has been validated across multiple populations internationally and provides an objective, portable, and relatively culture-independent assessment tool. It takes about five minutes to complete and can be administered by trained healthcare staff.

When should a patient with hepatic encephalopathy be admitted to the ICU?

ICU admission should be considered for patients with West Haven Grade III or IV hepatic encephalopathy. At Grade III, patients are at risk of aspiration due to impaired consciousness and may need airway protection. At Grade IV, intubation is typically required for airway management. ICU monitoring is also essential when cerebral edema is suspected (particularly in acute liver failure), when the patient is hemodynamically unstable, when the GCS score is declining rapidly, or when there is concurrent gastrointestinal bleeding, sepsis, or multi-organ failure. Patients at Grade III or above should have continuous monitoring with serial GCS assessments.

How is lactulose administered for hepatic encephalopathy?

Lactulose can be administered orally, via nasogastric tube, or as a rectal enema. For oral administration, the typical starting dose is 25 mL (about 17 g) two to four times daily, titrated to achieve two to three soft bowel movements per day. For patients who cannot take oral medications (such as those with Grade III-IV HE), lactulose enemas can be given rectally (300 mL of lactulose in 700 mL of water, retained for 30-60 minutes). Over-treatment leading to excessive diarrhea should be avoided, as dehydration and electrolyte disturbances can paradoxically worsen hepatic encephalopathy. Adequate hydration should be maintained throughout therapy.

What is the role of liver transplantation in hepatic encephalopathy?

Liver transplantation is the definitive treatment for hepatic encephalopathy that is refractory to medical management. In acute liver failure, the development of Grade III or IV HE is a strong indication for emergency transplant listing. In chronic liver disease, recurrent or persistent HE despite optimal therapy with lactulose and rifaximin is an indication for transplant evaluation, regardless of the MELD score. After transplantation, HE typically resolves, though some patients may have residual cognitive impairment. The transplant evaluation process includes assessment of overall medical fitness, psychosocial support, and the absence of contraindications such as active substance abuse or uncontrolled infection.

Can medications cause or worsen hepatic encephalopathy?

Yes, several classes of medications can precipitate or worsen hepatic encephalopathy. Benzodiazepines and opioids are particularly problematic as they directly depress central nervous system function. Diuretics (especially loop diuretics and thiazides) can cause dehydration and hypokalemia, both of which promote ammonia production and renal ammoniagenesis. Proton pump inhibitors have been associated with increased HE risk, possibly through alterations in gut microbiota. Sedative-hypnotics should be avoided in patients with cirrhosis. When analgesia is needed, acetaminophen at reduced doses (less than 2 g/day) is preferred over opioids. Medication reconciliation is an essential part of HE evaluation.

What is the difference between asterixis and tremor?

Asterixis and tremor are distinct neurological signs that are sometimes confused. A tremor is a fine, rhythmic, oscillatory movement that is typically constant in frequency and amplitude. Asterixis is a coarse, non-rhythmic, asynchronous flapping movement caused by intermittent loss of sustained muscle tone, rather than active muscle contraction. Asterixis is bilateral but asynchronous (the two hands do not flap in unison), while most tremors are more synchronized. This distinction is particularly important when evaluating patients with alcohol use disorder, where alcohol withdrawal tremor (a fine tremor) must be differentiated from HE-related asterixis, as the treatment approaches differ significantly.

How often should patients with cirrhosis be screened for hepatic encephalopathy?

Current guidelines recommend screening for minimal hepatic encephalopathy in patients with cirrhosis who report cognitive difficulties, have a history of driving accidents or job-related issues, or have risk factors such as a history of previous HE episodes, advanced liver disease (Child-Pugh B or C), large portosystemic shunts, or sarcopenia. While routine screening of all cirrhotic patients is not universally mandated, many experts advocate periodic assessment using validated tools such as the PHES, Animal Naming Test, or EncephalApp Stroop test, particularly in patients with decompensated cirrhosis. The frequency of screening should be individualized based on clinical risk factors.

What is the MELD score and how does it relate to hepatic encephalopathy?

The Model for End-Stage Liver Disease (MELD) score is a numerical scale (typically ranging from 6 to 40) used to assess the severity of chronic liver disease and prioritize patients for liver transplantation. It is calculated from serum bilirubin, creatinine, and INR (international normalized ratio). While hepatic encephalopathy is not directly included in the MELD calculation, it is a recognized exception point for transplant listing. Patients with recurrent or persistent HE may receive additional priority on the transplant waiting list through exception requests, recognizing that the MELD score alone may underestimate the severity of their condition and its impact on quality of life.

What nutritional recommendations are there for patients with hepatic encephalopathy?

Current nutritional guidelines for patients with HE emphasize adequate rather than restricted intake. The recommended daily protein intake is 1.2-1.5 g/kg/day, and caloric intake should be 35-40 kcal/kg/day. Small, frequent meals are preferred to avoid prolonged fasting, which increases protein catabolism and ammonia production. Vegetable and dairy protein sources may be better tolerated than meat protein in some patients. Branched-chain amino acid (BCAA) supplements can be considered for patients who cannot achieve adequate protein intake from diet alone. Late-evening snacks containing complex carbohydrates are recommended to prevent overnight fasting-induced catabolism. Sodium restriction is important for patients with ascites.

How does TIPS placement affect hepatic encephalopathy risk?

Transjugular intrahepatic portosystemic shunt (TIPS) placement creates a direct connection between the portal and systemic venous circulation, bypassing the liver. This reduces portal pressure (beneficial for variceal bleeding and refractory ascites) but increases the delivery of portal blood toxins, including ammonia, to the systemic circulation, potentially causing or worsening hepatic encephalopathy. HE develops in approximately 25-45% of patients after TIPS placement. Risk factors include older age, pre-existing HE, higher Child-Pugh class, and larger shunt diameter. Most post-TIPS HE responds to medical therapy, but approximately 5% of patients may require TIPS revision or occlusion.

What is the significance of sleep-wake inversion in hepatic encephalopathy?

Sleep-wake inversion, where patients experience excessive daytime sleepiness and nighttime wakefulness, is one of the earliest clinical features of hepatic encephalopathy and is typically seen at West Haven Grade I. It reflects disruption of the circadian rhythm and is thought to result from melatonin metabolism abnormalities due to impaired hepatic clearance. Sleep-wake inversion is clinically important because it may be the first symptom noticed by family members or caregivers, potentially alerting to the development of HE before more obvious signs appear. However, it is not specific to HE and can occur in other conditions affecting liver function or circadian regulation.

Can hepatic encephalopathy cause permanent brain damage?

Repeated episodes of overt hepatic encephalopathy can cause cumulative neurological injury, leading to persistent cognitive deficits even after clinical recovery. Studies have shown that patients with multiple previous HE episodes have more severe residual impairment than those with fewer episodes. The mechanisms of cumulative injury include repeated astrocyte swelling (Alzheimer type II astrocytosis), oxidative stress, neuroinflammation, and disruption of neural connectivity. While liver transplantation can halt the progression, some patients continue to have cognitive impairment post-transplant. This underscores the importance of preventing recurrent episodes through effective secondary prophylaxis with lactulose and rifaximin.

What is the Child-Pugh score and how does it relate to hepatic encephalopathy?

The Child-Pugh score is a classification system for assessing the severity of liver disease, incorporating five clinical parameters: total bilirubin, serum albumin, prothrombin time (INR), ascites, and hepatic encephalopathy. Each parameter is scored from 1 to 3 points, yielding a total score of 5-15. Hepatic encephalopathy contributes directly to the score: no encephalopathy scores 1 point, Grade I-II scores 2 points, and Grade III-IV scores 3 points. The total score classifies patients as Child-Pugh Class A (5-6 points, well-compensated), Class B (7-9 points, significant functional compromise), or Class C (10-15 points, decompensated disease). The score helps predict surgical risk and prognosis.

What are the key clinical features that distinguish each West Haven grade?

The key distinguishing features by grade are: Grade 0 (Minimal) – no clinical abnormalities, deficits detectable only by psychometric testing. Grade I – subtle personality changes, euphoria or anxiety, shortened attention span, sleep-wake inversion, impaired arithmetic ability. Grade II – lethargy, disorientation for time (the hallmark feature), inappropriate behavior, personality changes, asterixis typically first present. Grade III – somnolence to semistupor, responds to verbal stimuli, gross disorientation to time and place, bizarre behavior, confusion. Grade IV – coma, unresponsive or responsive only to painful stimuli, no higher cortical function. The transition from covert (0-I) to overt (II-IV) HE is marked by the presence of temporal disorientation.

Is hepatic encephalopathy a diagnosis of exclusion?

Yes, hepatic encephalopathy is fundamentally a diagnosis of exclusion. Before attributing altered mental status to HE, other potential causes must be systematically ruled out. These include intracranial pathology (hemorrhage, stroke, tumor, abscess), metabolic disturbances (hypoglycemia, hyponatremia, uremia, hypoxia, hypercarbia), infections (meningitis, encephalitis), alcohol withdrawal or intoxication, drug effects (sedatives, opioids, anticholinergics), and psychiatric conditions. Brain imaging (CT or MRI) should be performed when there is diagnostic uncertainty or when the patient does not respond as expected to HE treatment. This is especially important for first episodes in patients with compensated cirrhosis.

What is the Psychometric Hepatic Encephalopathy Score (PHES)?

The PHES is the best-validated psychometric battery for diagnosing minimal hepatic encephalopathy. It consists of five paper-and-pencil tests: Number Connection Test A (connects numbers 1-25 in sequence), Number Connection Test B (alternates between numbers and letters), the Digit Symbol Test (transcribes symbols using a coded key), the Serial Dotting Test (places dots in circles as quickly as possible), and the Line Tracing Test (traces a path between lines). Results are scored against age and education-adjusted normative data from the local population. A score of -4 or below (when each test contributes -1 to +1) is considered diagnostic of MHE. The PHES takes approximately 15-20 minutes to administer.

Conclusion

The West Haven Criteria remain the cornerstone of hepatic encephalopathy grading, providing a practical and widely recognized framework for assessing the severity of this complex neuropsychiatric complication of liver disease. From the subtle cognitive deficits of minimal HE to the profound unconsciousness of Grade IV coma, the criteria guide clinical decision-making about the appropriate level of care, treatment intensity, and prognosis communication. While the grading system has recognized limitations, particularly at the lower end of the scale, it continues to serve as the standard clinical tool recommended by major international hepatology societies.

Understanding the West Haven Criteria is essential for healthcare professionals who care for patients with liver disease, as timely recognition and appropriate grading of hepatic encephalopathy can significantly impact patient outcomes. The combination of systematic clinical assessment, identification and correction of precipitating factors, evidence-based pharmacological therapy with lactulose and rifaximin, and appropriate escalation of care for higher-grade HE forms the foundation of effective management. As research continues to refine our understanding of this condition, the principles embodied in the West Haven Criteria, systematic assessment, standardized grading, and treatment guided by severity, remain as relevant as ever in improving the lives of patients with hepatic encephalopathy worldwide.